Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas

American Journal of Pathology

Volumn 177, Issue 1, 2010, Pages 377-386

  Yoon, Sun Ok ^a   Zhang, Xin ^a   Freedman, Arnold S ^b   Zahrieh, David ^b   Lossos, Izidore S ^c   Li, Li ^a   Choi, Yong Sung ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD9 ANTIGEN; HISTONE DEACETYLASE INHIBITOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CELL STRAIN L3055; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; DNA MICROARRAY; DOWN REGULATION; EPIGENETICS; FLOW CYTOMETRY; FOLLICULAR DENDRITIC CELL; GENE EXPRESSION; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LYMPHOMA; LYMPHOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 77954602741     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100048     Document Type: Article

References (60)

1. Stevenson F, Sahota S, Zhu D, Ottensmeier C, Oscier D, Hamblin T: Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. Immunol Rev 1998, 162:247-259 (Pubitemid 28182140)
2. Kuppers R, Klein U, Hansmann ML, Rajewsky K: Cellular origin of human B-cell lymphomas. N Engl J Med 1999, 341:1520-1529 (Pubitemid 29526356)
3. Pascual V, Liu Y-J, Magalski A, de Bouteiller O, Banchereau J, Capra JD: Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med 1994, 180:329-339 (Pubitemid 24181081)
4. + germinal center (GC) B cells which occupy GC at a high frequency during the primary anti-hapten response in mice. Eur J Immunol 1997, 27:268-279
5. Kosco-Vilbois MH, Scheidegger D: Follicular dendritic cells: antigen retention. B cell activation, and cytokine production. Curr Top Microbiol Immunol 1995, 201:69-82
6. Choi YS: Differentiation and apoptosis of human germinal center B-lymphocytes. Immunol Res 1997, 16:161-174 (Pubitemid 27294587)
7. Petrasch S, Kosco M, Perez-Alvarez C, Schmitz J, Brittinger G: Proliferation of non-Hodgkin-lymphocytes in vitro is dependent upon follicular dendritic cell interactions. Br J Haema 1992, 80:21-26
8. Shiozawa E, Yamochi-Onizuka T, Yamochi T, Yamamoto Y, Naitoh H, Kawakami K, Nakamaki T, Tomoyasu S, Kushima M, Ota H: Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein. Pathol Res Pract 2003, 199:293-302
9. Choe J, Li L, Zhang X, Gregory CD, Choi YS: Distinct role of follicular dendritic cells and T cells in the proliferation, differentiation, and apoptosis of a centroblast cell line. L3055. J Immunol 2000, 164:56-63
10. Li L, Yoon SO, Fu DD, Zhang X, Choi YS: Novel follicular dendritic cell molecule, 8D6, collaborates with CD44 in supporting lymphomagenesis by a Burkitt lymphoma cell line, L3055. Blood 2004, 104:815-821
11. Maecker HT, Todd SC, Levy S: The tetraspanin superfamily: molecular facilitators. FASEB J 1997, 11:428-442
12. Sincock PM, Mayrhofer G, Ashman LK: Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63, and alpha5beta1 integrin. J Histochem Cytochem 1997, 45:515-525
13. Won WJ, Kearney JF: CD9 is a unique marker for marginal zone B cells, B1 cells, and plasma cells in mice. J Immunol 2002, 168:5605-5611
14. Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M, Romero M, Perdiguer L, Delgado M, Orfao A, Lazo PA: Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 2005, 19:1376-1383
15. Boucheix C, Rubinstein E: Tetraspanins. Cell Mol Life Sci 2001, 58:1189-1205
16. Hemler ME: Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005, 6:801-811
17. Zoller M: Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009, 9:40-55
18. Miyake M, Nakano K, Itoi SI, Koh T, Taki T: Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 1996, 56:1244-1249
19. Higashiyama M, Doi O, Kodama K, Yokouchi H, Adachi M, Huang CL, Taki T, Kasugai T, Ishiguro S, Nakamori S, Miyake M: Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 1997, 74:205-211
20. Huang CI, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M: Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 1998, 153:973-983
21. Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF, Akiyoshi T: Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 1998, 4:1507-1510 (Pubitemid 28265235)
22. Ko EM, Lee IY, Cheon IS, Kim J, Choi JS, Hwang JY, Cho JS, Lee DH, Kang D, Kim SH, Choe J: Monoclonal antibody to CD9 inhibits platelet-induced human endothelial cell proliferation. Mol Cells 2006, 22:70-77
23. Kim H-S, Zhang X, Choi YS: Activation and proliferation of follicular dendritic cell-like cells by activated T lymphocytes. J Immunol 1994, 153:2951-2961 (Pubitemid 24292521)
24. Kagami Y, Jung J, Choi YS, Osumi K, Nakamura S, Morishima Y, Seto M: Establishment of a follicular lymphoma cell line (FLK-1) dependent on follicular dendritic cell-like cell line HK. Leukemia 2001, 15:148-156
25. Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA: 2001, 98:31-36
26. Mutter GL, Baak JP, Fitzgerald JT, Gray R, Neuberg D, Kust GA, Gentleman R, Gullans SR, Wei LJ, Wilcox M: Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001, 83:177-185
27. Chao CH, Chen CM, Cheng PL, Shih JW, Tsou AP, Lee YH: DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer Res 2006, 66:6579-6588
28. Lung HL, Cheung AK, Xie D, Cheng Y, Kwong FM, Murakami Y, Guan XY, Sham JS, Chua D, Protopopov AI, Zabarovsky ER, Tsao SW, Stanbridge EJ, Lung ML: TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res 2006, 66:9385-9392 (Pubitemid 44623634)
29. Liton PB, Liu X, Stamer WD, Challa P, Epstein DL, Gonzalez P: Specific targeting of gene expression to a subset of human trabecular meshwork cells using the chitinase 3-like 1 promoter. Invest Ophthalmol Vis Sci 2005, 46:183-190
30. Shi GX, Harrison K, Wilson GL, Moratz C, Kehrl JH: RGS13 regulates germinal center B lymphocytes responsiveness to CXC chemokine ligand (CXCL)12 and CXCL13. J Immunol 2002, 169:2507-2515 (Pubitemid 34920995)
31. Sun H, Berquin IM, Edwards IJ: Omega-3 polyunsaturated fatty acids regulate syndecan-1 expression in human breast cancer cells. Cancer Res 2005, 65:4442-4447 (Pubitemid 40775684)
32. Atkinson B, Ernst CS, Ghrist BF, Herlyn M, Blaszczyk M, Ross AH, Herlyn D, Steplewski Z, Koprowski H: Identification of melanoma-associated antigens using fixed tissue screening of antibodies. Cancer Res 1984, 44:2577-2581 (Pubitemid 14108345)
33. Atkinson B, Ernst CS, Ghrist BF, Ross AH, Clark WH, Herlyn M, Herlyn D, Maul G, Steplewski Z, Koprowski H: Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors. Hybridoma 1985, 4:243-255 (Pubitemid 16220919)
34. Kondoh M, Ueda M, Ichihashi M, Mishima Y: Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-canceroses to invasive and metastatic melanomas. Melanoma Res 1993, 3:241-245 (Pubitemid 23289217)
35. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M: Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996, 56:1751-1755 (Pubitemid 26118208)
36. Guo X, Friess H, Graber HU, Kashiwagi M, Zimmermann A, Korc M, Buchler MW: KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res 1996, 56:4876-4880 (Pubitemid 26374422)
37. Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, Barrett JC: Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 1999, 59:5724-5731
38. Yang X, Wei L, Tang C, Slack R, Montgomery E, Lippman M: KAI1 protein is down-regulated during the progression of human breast cancer. Clin Cancer Res 2000, 6:3424-3429
39. Lossos IS, Alizadeh AA, Diehn M, Warnke R, Thorstenson Y, Oefner PJ, Brown PO, Botstein D, Levy R: Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 2002, 99:8886-8891
40. Freedman AS: Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program 2005, 314-320
41. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, Vinnicombe S, Waters R, Rohatiner AZ, Lister TA: Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007, 25:2426-2433 (Pubitemid 47007616)
42. Acker B, Hoppe RT, Colby TV, Cox RS, Kaplan HS, Rosenberg SA: Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1983, 1:11-16
43. Miyake M, Nakano K, Ieki Y, Adachi M, Huang CL, Itoi S, Koh T, Taki T: Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer. Cancer Res 1995, 55:4127-4131
44. Higashiyama M, Taki T, Ieki Y, Adachi M, Huang CL, Koh T, Kodama K, Doi O, Miyake M: Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 1995, 55:6040-6044
45. Cajot JF, Sordat I, Silvestre T, Sordat B: Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared with metastatic human colon carcinoma cells. Cancer Res 1997, 57:2593-2597
46. Houle CD, Ding XY, Foley JF, Afshari CA, Barrett JC, Davis BJ: Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol 2002, 86:69-78
47. Wang JC, Begin LR, Berube NG, Chevalier S, Aprikian AG, Gourdeau H, Chevrette M: Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res 2007, 13:2354-2361
48. De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, Atadja P, Coiteux V, Leleu X, Thielemans K, Van Camp B, Vanderkerken K, Van Riet I: Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 2008, 14:2918-2926
49. Takeda T, Hattori N, Tokuhara T, Nishimura Y, Yokoyama M, Miyake M: Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model. Cancer Res 2007, 67:1744-1749 (Pubitemid 46383401)
50. Ovalle S, Gutierrez-Lopez MD, Olmo N, Turnay J, Lizarbe MA, Majano P, Molina-Jimenez F, Lopez-Cabrera M, Yanez-Mo M, Sanchez-Madrid F, Cabanas C: The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. Int J Cancer 2007, 121:2140-2152
51. Zvereff V, Wang JC, Shun K, Lacoste J, Chevrette M: Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells. Br J Cancer 2007, 97:941-948 (Pubitemid 47519309)
52. Van Riet I, De Greef C, Aharchi F, Woischwill C, De Waele M, Bakkus M, Lacor P, Schots R, Van Camp B: Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2). Leukemia 1997, 11:284-293
53. De Bruyne E, Andersen TL, De Raeve H, Van Valckenborgh E, Caers J, Van Camp B, Delaisse JM, Van Riet I, Vanderkerken K: Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients. Leukemia 2006, 20:1870-1879
54. Masellis-Smith A, Shaw AR: CD9-regulated adhesion. Anti-CD9 monoclonal antibody induce pre-B cell adhesion to bone marrow fibroblasts through de novo recognition of fibronectin. J Immunol 1994, 152:2768-2777 (Pubitemid 24097972)
55. Longo N, Yanez-Mo M, Mittelbrunn M, de la Rosa G, Munoz ML, Sanchez-Madrid F, Sanchez-Mateos P: Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 2001, 98:3717-3726
56. Barreiro O, Yanez-Mo M, Sala-Valdes M, Gutierrez-Lopez MD, Ovalle S, Higginbottom A, Monk PN, Cabanas C, Sanchez-Madrid F: Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation. Blood 2005, 105:2852-2861 (Pubitemid 40446279)
57. Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, Klagsbrun M, Mekada E: The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol 1995, 128:929-938
58. Nakamura K, Mitamura T, Takahashi T, Kobayashi T, Mekada E: Importance of the major extracellular domain of CD9 and the epidermal growth factor (EGF)-like domain of heparin-binding EGF-like growth factor for up-regulation of binding and activity. J Biol Chem 2000, 275:18284-18290 (Pubitemid 30414782)
59. Yau JC, Dabbagh LK, Formenti KS, Coupland RW, Burns BF, Shaw AR: Expression of transmembrane 4 superfamily member, CD9, is related to improved progression-free survival in patients with diffuse non-Hodgkin's lymphoma. Oncol Rep 1998, 5:1507-1511
60. Zhong S, Fields CR, Su N, Pan YX, Robertson KD: Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 2007, 26:2621-2634 (Pubitemid 46632003)